Attune Neurosciences

Attune Neurosciences

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.attuneneuro.com/

Last Round

Grant

Apr 10, 2026

Total Funding Raised

$4.72M

Momentum Score

25 /100

Company Overview

Attune Neurosciences is a medical device company that develops non-invasive neurostimulation products to treat central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Mental Health, Health IoT

Business Model

B2B

Customer Profile

Government Contracts, Hardware + Subscription

AI Layer

Application

Keywords

low-intensity focused ultrasoundLIFUSneuromodulation devicedeep brain therapywearable ultrasoundnon-invasive brain stimulationneurotechfocused ultrasoundbrain modulationchronic pain therapybrain techdepression treatmentsleep disorder treatmentopioid use disorderEEG recordingadaptive stimulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attune Neurosciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Attune Neurosciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantApr 10, 2026
AcceleratorFeb 21, 2025
GrantSep 20, 2022
SeedOct 4, 2021
GrantSep 30, 2021

Key People

Founding team and executive leadership

Keith Murphy

Chief Technology Officer, Co-Founder

Founding Team

Rajiv Mahadevan

CEO

Executive Team

Attune Neurosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    $4M raised from ARPA-H

  • Jan 24, 2026

    Monthly visitors grew 98% MoM, reaching 2.2K.

Attune Neurosciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Attune Neurosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Attune Neurosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range19
Year Founded2019
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.